Migenix completes enrollment in phase 2b hepatitis study

By Elaine Rigoli

Tampa, Fla., June 15 - Migenix, Inc. said it has completed enrollment in a phase 2b study of celgosivir (MX-3253) in combination with Peg-Intron (peginterferon alfa-2b) and Pegetron (peginterferon alfa-2b plus ribavirin) for the treatment of hepatitis C virus (HCV) infection in genotype 1 patients who were non- responders or partial responders to previous treatment with pegylated interferon-based therapy.

A total of 57 subjects have been enrolled. The subjects will be treated for 12 weeks and results are expected to be available in October, according to a news release.

Celgosivir is an alpha-glucosidase 1 inhibitor and is the only oral anti-HCV drug in clinical development that acts on host-directed glycosylation, the release said.

In preclinical studies, celgosivir has demonstrated strong synergy with interferon-alpha (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and has the potential to be included as part of a combination therapeutic approach to improve efficacy.

This study is being supported in part through an agreement with Schering-Plough.

Migenix is a clinical-stage developer of drugs for infectious and degenerative diseases based in Vancouver, B.C., with U.S. operations in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.